KITE PHARMA INC's ticker is KITE and the CUSIP is 49803L109. A total of 227 filers reported holding KITE PHARMA INC in Q2 2017. The put-call ratio across all filers is 0.38 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $10,668,000 | +85.2% | 59,331 | +6.8% | 0.02% | +76.9% |
| Q2 2017 | $5,760,000 | +55.8% | 55,560 | +18.0% | 0.01% | +44.4% |
| Q1 2017 | $3,696,000 | +84.3% | 47,094 | +5.3% | 0.01% | +80.0% |
| Q4 2016 | $2,005,000 | -14.4% | 44,719 | +6.6% | 0.01% | -16.7% |
| Q3 2016 | $2,343,000 | +20.3% | 41,939 | +7.7% | 0.01% | 0.0% |
| Q2 2016 | $1,947,000 | +30.1% | 38,948 | +19.5% | 0.01% | +20.0% |
| Q1 2016 | $1,496,000 | -15.6% | 32,583 | +13.3% | 0.01% | -16.7% |
| Q4 2015 | $1,773,000 | +21.9% | 28,768 | +10.2% | 0.01% | +20.0% |
| Q3 2015 | $1,454,000 | -5.0% | 26,108 | +4.0% | 0.01% | 0.0% |
| Q2 2015 | $1,531,000 | +180.4% | 25,115 | +165.5% | 0.01% | +150.0% |
| Q1 2015 | $546,000 | +36.5% | 9,460 | +36.4% | 0.00% | +100.0% |
| Q4 2014 | $400,000 | – | 6,935 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wildcat Capital Management, LLC | 2,410,034 | $433,348,000 | 77.71% |
| COWEN INC. | 4,200,600 | $755,310,000 | 26.72% |
| Tyrus Capital S.A.M. | 1,314,812 | $236,416,000 | 18.49% |
| OMNI PARTNERS LLP | 661,711 | $118,982,000 | 15.19% |
| FNY Partners Fund LP | 379,510 | $68,239,000 | 11.61% |
| EQUITEC PROPRIETARY MARKETS, LLC | 240,100 | $43,172,000 | 10.15% |
| EQUITEC PROPRIETARY MARKETS, LLC | 227,500 | $40,907,000 | 9.62% |
| GARDNER LEWIS ASSET MANAGEMENT L P | 773,817 | $139,140,000 | 8.89% |
| Quad Capital Management Advisors LLC | 192,537 | $34,620,000 | 7.10% |
| Avoro Capital Advisors LLC | 496,983 | $89,363,000 | 6.93% |